Smoliga James M, Blanchard Otis
Department of Physical Therapy, School of Health Sciences, High Point University, High Point, NC 27262, USA.
Wilmore Labs LLC, San Antonio, TX 78250, USA.
Molecules. 2014 Oct 24;19(11):17154-72. doi: 10.3390/molecules191117154.
Resveratrol has emerged as a leading candidate for improving healthspan through potentially slowing the aging process and preventing chronic diseases. The poor bioavailability of resveratrol in humans has been a major concern for translating basic science findings into clinical utility. Although a number of positive findings have emerged from human clinical trials, there remain many conflicting results, which may partially be attributed to the dosing protocols used. A number of theoretical solutions have been developed to improve the bioavailability of resveratrol, including consumption with various foods, micronized powders, combining it with additional phytochemicals, controlled release devices, and nanotechnological formulations. While laboratory models indicate these approaches all have potential to improve bioavailability of resveratrol and optimize its clinical utility, there is surprisingly very little data regarding the bioavailability of resveratrol in humans. If bioavailability is indeed a limitation in the clinical utility of resveratrol, there is a need to further explore methods to optimize bioavailability in humans. This review summarizes the current bioavailability data, focusing on data from humans, and provides suggested directions for future research in this realm.
白藜芦醇已成为通过潜在地减缓衰老过程和预防慢性疾病来改善健康寿命的主要候选物质。白藜芦醇在人体中的生物利用度较差，这一直是将基础科学研究成果转化为临床应用的主要关注点。尽管人体临床试验已经出现了一些积极的结果，但仍有许多相互矛盾的结果，这可能部分归因于所使用的给药方案。为了提高白藜芦醇的生物利用度，已经开发了一些理论解决方案，包括与各种食物一起食用、微粉化粉末、与其他植物化学物质结合、控释装置和纳米技术制剂。虽然实验室模型表明这些方法都有可能提高白藜芦醇的生物利用度并优化其临床应用，但令人惊讶的是，关于白藜芦醇在人体中的生物利用度的数据非常少。如果生物利用度确实是白藜芦醇临床应用的一个限制因素，那么就需要进一步探索优化人体生物利用度的方法。这篇综述总结了当前的生物利用度数据，重点是来自人体的数据，并为该领域未来的研究提供了建议方向。
